Design and selection of toca 511 for clinical use: Modified retroviral replicating vector with improved stability and gene expression

Omar D. Perez, Christopher R. Logg, Kei Hiraoka, Oscar Diago, Ryan Burnett, Akihito Inagaki, Dawn Jolson, Karin Amundson, Taylor Buckley, Dan Lohse, Amy Lin, Cindy Burrascano, Carlos Ibanez, Noriyuki Kasahara, Harry E. Gruber, Douglas J. Jolly

Research output: Contribution to journalArticle

63 Citations (Scopus)

Abstract

Retroviral replicating vectors (RRVs) are a nonlytic alternative to oncolytic replicating viruses as anticancer agents, being selective both for dividing cells and for cells that have defects in innate immunity and interferon responsiveness. Tumor cells fit both these descriptions. Previous publications have described a prototype based on an amphotropic murine leukemia virus (MLV), encoding yeast cytosine deaminase (CD) that converts the prodrug 5-fluorocytosine (5-FC) to the potent anticancer drug, 5-fluorouracil (5-FU) in an infected tumor. We report here the selection of one lead clinical candidate based on a general design goal to optimize the genetic stability of the virus and the CD activity produced by the delivered transgene. Vectors were tested for titer, genetic stability, CD protein and enzyme activity, ability to confer susceptibility to 5-FC, and preliminary in vivo antitumor activity and stability. One vector, Toca 511, (aka T5.0002) encoding an optimized CD, shows a threefold increased specific activity in infected cells over infection with the prototype RRV and shows markedly higher genetic stability. Animal testing demonstrated that Toca 511 replicates stably in human tumor xenografts and, after 5-FC administration, causes complete regression of such xenografts. Toca 511 (vocimagene amiretrorepvec) has been taken forward to preclinical and clinical trials.

Original languageEnglish (US)
Pages (from-to)1689-1698
Number of pages10
JournalMolecular Therapy
Volume20
Issue number9
DOIs
StatePublished - Sep 2012
Externally publishedYes

Fingerprint

Cytosine Deaminase
Flucytosine
Gene Expression
Heterografts
Oncolytic Viruses
Murine Leukemia Viruses
Neoplasms
Prodrugs
Transgenes
Innate Immunity
Fluorouracil
Antineoplastic Agents
Interferons
Yeasts
Clinical Trials
Viruses
Enzymes
Infection
Pharmaceutical Preparations
Proteins

ASJC Scopus subject areas

  • Molecular Biology
  • Molecular Medicine
  • Genetics
  • Drug Discovery
  • Pharmacology

Cite this

Perez, O. D., Logg, C. R., Hiraoka, K., Diago, O., Burnett, R., Inagaki, A., ... Jolly, D. J. (2012). Design and selection of toca 511 for clinical use: Modified retroviral replicating vector with improved stability and gene expression. Molecular Therapy, 20(9), 1689-1698. https://doi.org/10.1038/mt.2012.83

Design and selection of toca 511 for clinical use : Modified retroviral replicating vector with improved stability and gene expression. / Perez, Omar D.; Logg, Christopher R.; Hiraoka, Kei; Diago, Oscar; Burnett, Ryan; Inagaki, Akihito; Jolson, Dawn; Amundson, Karin; Buckley, Taylor; Lohse, Dan; Lin, Amy; Burrascano, Cindy; Ibanez, Carlos; Kasahara, Noriyuki; Gruber, Harry E.; Jolly, Douglas J.

In: Molecular Therapy, Vol. 20, No. 9, 09.2012, p. 1689-1698.

Research output: Contribution to journalArticle

Perez, OD, Logg, CR, Hiraoka, K, Diago, O, Burnett, R, Inagaki, A, Jolson, D, Amundson, K, Buckley, T, Lohse, D, Lin, A, Burrascano, C, Ibanez, C, Kasahara, N, Gruber, HE & Jolly, DJ 2012, 'Design and selection of toca 511 for clinical use: Modified retroviral replicating vector with improved stability and gene expression', Molecular Therapy, vol. 20, no. 9, pp. 1689-1698. https://doi.org/10.1038/mt.2012.83
Perez, Omar D. ; Logg, Christopher R. ; Hiraoka, Kei ; Diago, Oscar ; Burnett, Ryan ; Inagaki, Akihito ; Jolson, Dawn ; Amundson, Karin ; Buckley, Taylor ; Lohse, Dan ; Lin, Amy ; Burrascano, Cindy ; Ibanez, Carlos ; Kasahara, Noriyuki ; Gruber, Harry E. ; Jolly, Douglas J. / Design and selection of toca 511 for clinical use : Modified retroviral replicating vector with improved stability and gene expression. In: Molecular Therapy. 2012 ; Vol. 20, No. 9. pp. 1689-1698.
@article{af47f047c28e4143a3b90980fad0ca5e,
title = "Design and selection of toca 511 for clinical use: Modified retroviral replicating vector with improved stability and gene expression",
abstract = "Retroviral replicating vectors (RRVs) are a nonlytic alternative to oncolytic replicating viruses as anticancer agents, being selective both for dividing cells and for cells that have defects in innate immunity and interferon responsiveness. Tumor cells fit both these descriptions. Previous publications have described a prototype based on an amphotropic murine leukemia virus (MLV), encoding yeast cytosine deaminase (CD) that converts the prodrug 5-fluorocytosine (5-FC) to the potent anticancer drug, 5-fluorouracil (5-FU) in an infected tumor. We report here the selection of one lead clinical candidate based on a general design goal to optimize the genetic stability of the virus and the CD activity produced by the delivered transgene. Vectors were tested for titer, genetic stability, CD protein and enzyme activity, ability to confer susceptibility to 5-FC, and preliminary in vivo antitumor activity and stability. One vector, Toca 511, (aka T5.0002) encoding an optimized CD, shows a threefold increased specific activity in infected cells over infection with the prototype RRV and shows markedly higher genetic stability. Animal testing demonstrated that Toca 511 replicates stably in human tumor xenografts and, after 5-FC administration, causes complete regression of such xenografts. Toca 511 (vocimagene amiretrorepvec) has been taken forward to preclinical and clinical trials.",
author = "Perez, {Omar D.} and Logg, {Christopher R.} and Kei Hiraoka and Oscar Diago and Ryan Burnett and Akihito Inagaki and Dawn Jolson and Karin Amundson and Taylor Buckley and Dan Lohse and Amy Lin and Cindy Burrascano and Carlos Ibanez and Noriyuki Kasahara and Gruber, {Harry E.} and Jolly, {Douglas J.}",
year = "2012",
month = "9",
doi = "10.1038/mt.2012.83",
language = "English (US)",
volume = "20",
pages = "1689--1698",
journal = "Molecular Therapy",
issn = "1525-0016",
publisher = "Nature Publishing Group",
number = "9",

}

TY - JOUR

T1 - Design and selection of toca 511 for clinical use

T2 - Modified retroviral replicating vector with improved stability and gene expression

AU - Perez, Omar D.

AU - Logg, Christopher R.

AU - Hiraoka, Kei

AU - Diago, Oscar

AU - Burnett, Ryan

AU - Inagaki, Akihito

AU - Jolson, Dawn

AU - Amundson, Karin

AU - Buckley, Taylor

AU - Lohse, Dan

AU - Lin, Amy

AU - Burrascano, Cindy

AU - Ibanez, Carlos

AU - Kasahara, Noriyuki

AU - Gruber, Harry E.

AU - Jolly, Douglas J.

PY - 2012/9

Y1 - 2012/9

N2 - Retroviral replicating vectors (RRVs) are a nonlytic alternative to oncolytic replicating viruses as anticancer agents, being selective both for dividing cells and for cells that have defects in innate immunity and interferon responsiveness. Tumor cells fit both these descriptions. Previous publications have described a prototype based on an amphotropic murine leukemia virus (MLV), encoding yeast cytosine deaminase (CD) that converts the prodrug 5-fluorocytosine (5-FC) to the potent anticancer drug, 5-fluorouracil (5-FU) in an infected tumor. We report here the selection of one lead clinical candidate based on a general design goal to optimize the genetic stability of the virus and the CD activity produced by the delivered transgene. Vectors were tested for titer, genetic stability, CD protein and enzyme activity, ability to confer susceptibility to 5-FC, and preliminary in vivo antitumor activity and stability. One vector, Toca 511, (aka T5.0002) encoding an optimized CD, shows a threefold increased specific activity in infected cells over infection with the prototype RRV and shows markedly higher genetic stability. Animal testing demonstrated that Toca 511 replicates stably in human tumor xenografts and, after 5-FC administration, causes complete regression of such xenografts. Toca 511 (vocimagene amiretrorepvec) has been taken forward to preclinical and clinical trials.

AB - Retroviral replicating vectors (RRVs) are a nonlytic alternative to oncolytic replicating viruses as anticancer agents, being selective both for dividing cells and for cells that have defects in innate immunity and interferon responsiveness. Tumor cells fit both these descriptions. Previous publications have described a prototype based on an amphotropic murine leukemia virus (MLV), encoding yeast cytosine deaminase (CD) that converts the prodrug 5-fluorocytosine (5-FC) to the potent anticancer drug, 5-fluorouracil (5-FU) in an infected tumor. We report here the selection of one lead clinical candidate based on a general design goal to optimize the genetic stability of the virus and the CD activity produced by the delivered transgene. Vectors were tested for titer, genetic stability, CD protein and enzyme activity, ability to confer susceptibility to 5-FC, and preliminary in vivo antitumor activity and stability. One vector, Toca 511, (aka T5.0002) encoding an optimized CD, shows a threefold increased specific activity in infected cells over infection with the prototype RRV and shows markedly higher genetic stability. Animal testing demonstrated that Toca 511 replicates stably in human tumor xenografts and, after 5-FC administration, causes complete regression of such xenografts. Toca 511 (vocimagene amiretrorepvec) has been taken forward to preclinical and clinical trials.

UR - http://www.scopus.com/inward/record.url?scp=84867077136&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867077136&partnerID=8YFLogxK

U2 - 10.1038/mt.2012.83

DO - 10.1038/mt.2012.83

M3 - Article

C2 - 22547150

AN - SCOPUS:84867077136

VL - 20

SP - 1689

EP - 1698

JO - Molecular Therapy

JF - Molecular Therapy

SN - 1525-0016

IS - 9

ER -